Clinical Dosage Determination of a New Aromatase Inhibitor, Anastrozole, in Postmenopausal Japanese Women with Advanced Breast Cancer

Author： Nomura Y.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.20, Iss.5, 2000-11, pp. : 357-369

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anastrozole: A Review of its Use in the Management of Postmenopausal Women with Advanced Breast Cancer

By Wiseman L.R.   Adkins J.C.  

Drugs & Aging, Vol. 13, Iss. 4, 1998-10 ,pp. : 321-332

Adis International

Access to resources Recommend Favorite

Risedronic acid prevents bone loss in postmenopausal women with breast cancer, with or without aromatase inhibitor (AI) therapy,

By  

Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Anastrozole: A Review of its Use in Postmenopausal Women with Early-Stage Breast Cancer

By Sanford Mark   Plosker Greg L.  

Drugs, Vol. 68, Iss. 9, 2008-01 ,pp. : 1319-1340

Adis International

Access to resources Recommend Favorite

Anastrozole use does not appear to change bone mineral density (BMD) or bone turnover markers in postmenopausal Japanese women with breast cancer

By  

Reactions Weekly, Vol. 1, Iss. 1122, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Fulvestrant – a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer

By Possinger Kurt  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2549-2558

Informa Healthcare

Access to resources Recommend Favorite